Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 120

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 120
---
 Ltd., Sophia Genetics SA and CIBIC, for reagents, as well as sequencers and other equipment and materials which we use in our laboratory operations, and GNX Data Systems Ltd platform for genomic variant analysis. Pursuant to the Commercialization Agreement, we have established arrangements with CIBIC for the supply of reagents and equipment required for our operations. Further, as CIBIC sources reagents from Illumina, we also have the option to purchase the reagents directly from Illumina, if required. Additionally, we plan to develop strategic partnerships with other laboratories and players in the healthcare sector that share similar supply chain risks. These partnerships could amplify the effects of any supply chain issues. Currently, we do not have short- or long -termsupply agreements for our Argentine Wet Lab, and these suppliers could cease supplying these materials and equipment at any time or fail to provide us with sufficient quantities of materials or materials that meet our specifications. Our laboratory operations in Argentina, as well as those of our partner laboratories, could be interrupted if we encounter delays or difficulties in securing these reagents, sequencers or other equipment or materials, and if we cannot obtain an acceptable substitute. Any such interruption could significantly affect our business, financial condition, results of operations and reputation. As an alternative to CIBIC, we may rely on Illumina for the supply of next generation sequencers, associated reagents and maintenance and repair services for these sequencers. Any disruption in Illumina’s operations could affect our supply chain and laboratory operations in the short term, as Illumina is also a supplier to CIBIC. Additionally, transitioning to alternative providers could require a substantial amount of time to integrate replacement equipment and reagents into our laboratory operations potentially affecting our ability to provide our services during the transition period. We believe that there are only a few other manufacturers that are currently capable of supplying and servicing the equipment necessary for our laboratory and our partner laboratories’ operations, including sequencers and various associated reagents. The use of equipment or materials provided by these replacement suppliers would require us to alter these laboratory operations which may have an impact in the accuracy of our genetic test results. We will have to depend on these other parties to perform effectively on a timely basis and to comply with regulatory requirements. Transitioning to a new supplier would be time consuming and expensive, may result in interruptions in our and our partners’ laboratory operations, could affect the performance specifications of these laboratory operations or could require that we revalidate our tests. We cannot assure you that we will be able to secure